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Neurofilament light chain
A prognostic biomarker in amyotrophic lateral sclerosis
ABSTRACT
Objective: To test blood and CSF neurofilament light chain (NfL) levels in relation to disease pro-
gression and survival in amyotrophic lateral sclerosis (ALS).
Methods: Using an electrochemiluminescence immunoassay, NfL levels were measured in sam-
ples from 2 cohorts of patients with sporadic ALS and healthy controls, recruited in London
(ALS/control, plasma: n 5 103/42) and Oxford (ALS/control, serum: n 5 64/36; paired CSF:
n 5 38/20). NfL levels in patients were measured at regular intervals for up to 3 years. Change
in ALS Functional Rating Scale–Revised score was used to assess disease progression. Survival
was evaluated using Cox regression and Kaplan–Meier analysis.
Results: CSF, serum, and plasma NfL discriminated patients with ALS from healthy controls
with high sensitivity (97%, 89%, 90%, respectively) and specificity (95%, 75%, 71%,
respectively). CSF NfL was highly correlated with serum levels (r 5 0.78, p , 0.0001). Blood
NfL levels were approximately 4 times as high in patients with ALS compared with controls in
both cohorts, and maintained a relatively constant expression during follow-up. Blood NfL
levels at recruitment were strong, independent predictors of survival. The highest tertile of
blood NfL at baseline had a mortality hazard ratio of 3.91 (95% confidence interval 1.98–
7.94, p , 0.001).
Conclusion: Blood-derived NfL level is an easily accessible biomarker with prognostic value in
ALS. The individually relatively stable levels longitudinally offer potential for NfL as a pharmaco-
dynamic biomarker in future therapeutic trials.
Classification of evidence: This report provides Class III evidence that the NfL electrochemilumi-
nescence immunoassay accurately distinguishes patients with sporadic ALS from healthy
controls. Neurology® 2015;84:2247–2257
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; CI 5 confidence interval; Nf 5 neurofilament; NfH 5 neurofilament heavy chain; NfL 5
neurofilament light chain; PRB 5 progression rate at baseline; PRL 5 progression rate at last visit.
Various factors militate against the development of reliable biomarkers in amyotrophic lateral
sclerosis (ALS), including clinical heterogeneity, variable rate of progression, and the lack of a
recognizable preclinical state of this fatal neurodegenerative disorder. An easily accessible and
reproducible prognostic biomarker would help patient stratification, improving assessment of
individual prognosis and care-planning. It might also have potential as a pharmacodynamic mea-
sure of therapeutic response.
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The longitudinal assessment of a putative
biomarker would allow a more reliable inter-
pretation of the biomarker’s behavior when
monitoring treatment response. Blood-based
biomarkers are preferable because they
require minimally invasive collection com-
pared to CSF sampling. Neurofilaments
(Nfs), the main byproducts of neuroaxonal
breakdown, are potential “universal” bio-
markers of neurodegeneration.1 Nf levels in
CSF from patients with ALS increase signifi-
cantly compared to other neurodegenerative
disorders2–4 or to ALS-mimics,5 and show a
robust interlaboratory reproducibility com-
pared to other biomarkers.6 Nf bioavailability
and measurement depend on matrix-related
biological phenomena such as protein aggre-
gation, as recently reported.7,8
In this study, we examined the prognostic
value in ALS of neurofilament light chain
(NfL), one of the main constituents of neu-
rons and axons, building on previous small
cross-sectional studies9–11 to evaluate the tem-
poral profile of NfL expression in plasma,
serum, and CSF from patients with ALS.
METHODS Standard protocol approvals, registrations,
and patient consents. Approvals were obtained from the East
London and the City Research Ethics Committee 1 (09/
H0703/27) and South Central Oxford Ethics Committee B
(08/H0605/85). All participants provided written consent (or
gave verbal permission for a carer to sign on their behalf).
Participants and sampling. This study included 103 patients
with ALS and 42 healthy controls from a London cohort and 64
patients with ALS and 36 healthy controls from an Oxford
cohort. Patients with ALS were diagnosed according to standard
criteria,12 having been examined by experienced ALS neurologists
(London cohort: A.M., K.S., R.O., R.H., M.F.; Oxford cohort:
M.R.T., K.T.). Those with a family history of ALS or frontotem-
poral dementia, or known to carry a genetic mutation linked to
ALS or frontotemporal dementia, were excluded to minimize any
potential biases. Healthy controls were typically spouses and
friends of patients. Exclusion criteria included neurologic comor-
bidities likely to affect Nf bioavailability.13–15
Baseline NfL levels were measured in plasma, serum, and
CSF samples. Serial plasma samples and clinical information were
obtained, on average, every 2 to 4 months from 67 of the 103 pa-
tients with ALS recruited in London. Serum and CSF samples
(where possible) were collected every 6 months from 43 and 24
of the 64 patients with ALS in Oxford. No selection criteria were
applied to individuals with ALS sampled longitudinally, other
than their willingness to donate further samples. Symptom onset
was defined as first patient-reported weakness. Progression rate
was calculated at baseline (PRB) or last visit (PRL) as 48 minus
the ALS Functional Rating Scale–Revised score, divided by the
disease duration from onset of symptoms. Progression rate less
than 0.5, between 0.5 and 1.0, and more than 1.0 (point/month)
was defined as slow (ALS-slow), intermediate (ALS-intermedi-
ate), and fast progressing ALS (ALS-fast), respectively. Use of
riluzole (or not) at the time of sampling was recorded.
Sample analysis. Plasma, serum, and CSF samples were pro-
cessed and aliquoted within 1 hour from collection and frozen
at 280°C, following standard consensus procedures.16 An elec-
trochemiluminescence immunoassay was used to quantify NfL as
previously described9; the investigators were blinded to clinical
data. ALS and control samples were evenly distributed on each
plate and measured in duplicate at the same dilution. Each plate
contained calibrators (0–10,000 pg/mL) and quality controls.
The interassay coefficients of variance were mostly below 10%
and the mean intraassay coefficients of variance were below 10%.
Linearity of the NfL assay was established (0–50,000 pg/mL) as
previously reported.9
Statistical analysis. Continuous variables were summarized in
median (interquartile range); hence, nonparametric analysis for
group comparisons and correlation analysis. Receiver operating
characteristic curve analysis was used to assess assay sensitivity/
specificity. We used log rank analysis to compare survival (fixed
date was used to censor data for survival analysis) and multilevel
random intercept models with a linear slope to examine NfL lon-
gitudinal trajectories (MLwiN version 2.30, from Stata version
13.1; runmlwin command)17 for the first 15 months of the
follow-up period in 3 ALS progression subgroups: slow,
intermediate, and fast progressors. A natural log transformation
was used to normalize the measurements. Each ALS progression
group was included as a categorical fixed effect; we also included
an interaction between the ALS progression categories and time
to assess whether the rate of change in NfL differed by ALS
progression rate. NfL change was jointly modeled with the time
to death within the 15-month follow-up period to account for
any informative dropout.18 Cox regression analysis of survival by
NfL at baseline and other covariates was tested in the London and
Oxford cohorts separately and then combined (adjusting for
study center). The matched serum and plasma NfL levels from
healthy controls in a previous study showed high correlation (n5
25, Spearman r5 0.93, p, 0.0001) and strong agreement using
Bland-Altman method comparison (bias: 3.92; serum-plasma;
95% confidence interval [CI]: 22.41, 10.25; 95% limits of
agreement: 226.15, 33.99; Kuhle et al., unpublished data).
We conducted analyses of the 2 cohorts combined, using the
corresponding NfL data (serum or plasma) from each cohort.
However, in recognition that NfL data from the 2 cohorts were
different (albeit highly correlated) measures, we used cohort-
specific tertile cutoff levels, and we adjusted Cox regression and
Kaplan–Meier survival analyses by center. A p value of less than
0.05 was considered statistically significant.
RESULTS Demographic and clinical characteristics
of the London and Oxford cohorts are summarized
in table e-1 on the Neurology® Web site at
Neurology.org. Table 1 reports the baseline blood
and CSF NfL levels along with the demographic
and clinic characteristics of the cohorts.
Cross-sectional analyses. NfL levels in CSF (Oxford cohort),
serum (Oxford cohort), and plasma (London cohort).NfL lev-
els were higher in patients with ALS than in controls in
all biofluids measured (p , 0.0001; figure 1, A–C,
left). Receiver operating characteristic analysis showed
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Table 1 Summary of blood NfL levels (London, Oxford, and combined cohorts) and of CSF NfL levels (Oxford) used for cross-sectional analysis
ALS, NfL levels Controls, NfL levels
London (plasma)
(n 5 103)
Oxford (serum)
(n 5 64)
Combined (blood)
(n 5 67)
Oxford (CSF)
(n 5 38)
London (plasma)
(n 5 42)
Oxford (serum)
(n 5 36)
Combined (blood)
(n 5 78)
Oxford (CSF)
(n 5 20)
Sex
Male 82.3 (46.5, 150)Ref 90 (53, 146) 84.9 (50.8, 146.3)Ref 8,948 (4,651, 12,315) 30.6 (22, 86.9) 23 (12, 46) 29.9 (15.9, 49.5) 614.8 (494.9, 1,101)
Female 142.9 (76.1, 218.8)a 90 (59, 183) 125.7 (62, 214.7)b 4,630 (3,406, 10,247) 25.2 (16.7, 28.7) 20 (10.5, 37.5) 23.2 (14.2, 38.0) 426.5 (275.3, 467.4)
Age of sampling at baseline, y
<60 92.9 (40.3, 158) 69 (40, 116) 78 (40.2, 146) 7,570 (4,630, 9,483) 27.9 (19.2, 62.2) 14 (9, 33) 21.9 (12, 38.4) 460.7 (290.6, 554.4)
60–69 99.7 (57.5, 156.1) 113 (62, 215) 99.9 (57.6, 167) 7,993 (3,950, 14,409) 22 (13.2, 34.4) 31 (22, 102.5) 27 (18.8, 42.9) 884.1 (443.3, 1,603)
70–79 111.6 (61.6, 157.6) 105 (71.5, 133.3) 105 (61.7, 154) 5,897 (4,284, 10,202) 25.7 (18.4, 38.7) 28 (23, 33) 25.7 (20.7, 35.9) 1,098 (1,098, 1,098)
‡80 117.2 (57.6, 231.7) 122.5 (39, 206) 117.2 (54.9, 216.7) 10,558 (10,558, 10,558) 82.3 (82.3, 82.3) — 82.3 (82.3, 82.3) —
Age at onset, y
<60 92.9 (40.25, 158) 69 (40, 116)Ref 76 (40.2, 146) 7,570 (4,474, 9,284)
60–69 100.1 (56.1, 152.5) 113 (79, 215)b 106.1 (57.6, 157.4) 5,505 (3,388, 13,954)
70–79 95.3 (61.7, 158) 103 (39, 129) 99.2 (61.7, 154.5) 9,189 (5,481, 11,732)
‡80 198.5 (59, 266.1) 206 (206, 206) 202.3 (66.8, 254.6) 10,558 (10,558, 10,558)
Site of symptom onset
Limb 94.3 (53.7, 159.9) 86 (42, 151) 90.1 (53.1, 154.3) 7,037 (4,154, 10,558)
Bulbar 142.5 (55.13, 200.7) 113 (75, 282) 132 (61.5, 230.9) 9,189 (4,673, 13,954)
Bothc 118.5 (95.3, 141.6) — 118.5 (95.3, 141.6) —
Duration to baseline, mo
<12 148.2 (72.98, 217)a 155 (103, 255.5)a 150 (95.23, 214.6)d 10,949 (7,210, 13,852)a
12–24 121.5 (64.53, 214.8)b 122.5 (86.3, 151.8)b 121.5 (70.2, 210.5)d 9,284 (5,245, 9,189)a
25–36 82.3 (57.4, 155.6) 79 (41.5, 104.8) 82 (55.9, 116.5) 4,154 (3,388, 9,189)
>36 52.3 (27.1, 98.8)Ref 55 (26.5, 105.5)Ref 53.4 (27.3, 98.9)Ref 4,093 (2,767, 4,785)Ref
ALSFRS-R score
47–40 66.9 (38.9, 143.6) 94 (50.5, 108.5) 81.6 (39.9, 132.6) 6,289 (5,050, 9,535)
39–26 104.4 (62.4, 158.6) 90 (54, 151.5) 99.7 (60, 157.3) 8,259 (4,108, 12,607)
£25 147.7 (48.9, 253.9) 171.5 (38, 305) 147.7 (48.4, 261.8) 23,286 (23,286, 23,286)
Progression rate at baseline
Slow: <0.5 66.9 (46.5, 117.3)Ref 64.5 (38, 106)Ref 66.9 (39.5, 107)Ref 4,489 (3,245, 5,701)Ref
Intermediate: 0.5–1.0 113.7 (59.8, 151.4) 116 (79.5, 48.5)b 116 (62, 150)b 9,189 (4,640, 13,985)e
Fast: >1.0 180.1 (115.9, 277.4)d 156 (99, 271)d 161.7 (110.6, 268.6)f 11,340 (8,607, 15,625)g
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an area under the curve for CSF of 0.9987, for serum
0.8626, and 0.8687 for plasma (p, 0.0001; figure 1,
A–C, right). Cutoff levels provided clear separation of
patients with ALS from controls in all biofluids tested
(figure 1, A–C, right).
Correlation between CSF and serum NfL levels.NfL lev-
els in matched CSF and serum samples were highly
correlated (ALS: r 5 0.78, p , 0.0001; controls:
r 5 0.57, p 5 0.008; figure 1D). CSF NfL values
were 73.8-fold (interquartile range: 51.9–91.5) and
34.6-fold (17.0–42.0) higher than serum levels in
ALS and controls, respectively (p , 0.0001).
Blood NfL levels vs disease progression and duration in
ALS. In both London and Oxford cohorts, blood NfL
levels in ALS-fast were significantly higher than in
ALS-slow (London: p 5 0.0002; Oxford: p 5
0.0007), but not in ALS-intermediate (p 5 0.0616
and 0.4809, respectively) (table 1). The higher
expression of NfL in patients with ALS-fast was con-
firmed by the strong correlation between blood NfL
levels at baseline and PRB in London (Spearman r5
0.47, p , 0.0001) and Oxford (r 5 0.51, p ,
0.0001) cohorts (figure 1E) as well as with PRL in
London (r 5 0.48, p , 0.0001) and Oxford (r 5
0.53, p , 0.0001). PRB was strongly correlated with
PRL in both cohorts (London/Oxford: r 5
0.93/0.95, p , 0.0001 for both). There was a nega-
tive correlation between blood NfL levels and
disease duration to baseline (London/Oxford: r 5
20.36/20.50; p5 0.0002/p, 0.0001), while dura-
tion to baseline was also negatively correlated with
disease progression (London/Oxford: for PRB: r 5
20.62/20.86; for PRL: r 5 20.67/20.87; p ,
0.0001 for both).
Effect of sex in blood NfL levels.The male to female ratio
in London, Oxford, and in the combined cohorts was
approximately 2:1 (table e-1). In the London cohort
and in the combined cohorts, plasma NfL levels were
significantly higher in female than in male participants
(table 1); London female patients with ALS were older
and in a more advanced stage of the disease, while
Oxford female and male patients with ALS had similar
age and disease severity (table e-2A).
Longitudinal analyses. The average trajectories of natu-
ral log NfL levels from the multilevel model analysis
over the first 15 months of the follow-up period in
patients with ALS subdivided according to PRL are
shown in figure 2 (solid lines), along with the
trajectories of the observed log NfL levels for each
individual patient with ALS (dashed lines, figure 2).
Because PRB and PRL are highly correlated, PRL was
chosen for stratification of patients with ALS as more
representative of disease progression.
A summary of the statistical analysis is shown in
table e-3. Baseline natural log plasma, serum, and
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Figure 1 Summary of the cross-sectional analyses of NfL levels in the Oxford and London cohorts
NfL levels (median [interquartile range]) in patients with amyotrophic lateral sclerosis and controls in the cross-sectional
analysis using (A) CSF, (B) serum, and (C) plasma (Mann–Whitney U test). Results of receiver operating characteristic anal-
ysis are shown in the right panel. (D) Matched CSF and serum NfL levels are strongly correlated in controls and in patients
with ALS. (E) Blood NfL levels are strongly correlated with progression rate at baseline in both London and Oxford cohorts.
AUC 5 area under the curve; NfL 5 neurofilament light chain.
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CSF NfL levels were higher in ALS-fast than in ALS-
slow (table e-3, exposure group A) in both London
and Oxford cohorts. There was little or no change
in plasma NfL levels over time in any of the ALS pro-
gression groups in London, while in Oxford, there
was a small temporal increase of serum NfL in the
ALS-fast group (n 5 10; increase per month 4.6%
[95% CI: 1.6%, 7.7%]). In Oxford, only 22 of 38
patients went on to have follow-up lumbar punctures,
and the follow-up period for the ALS-fast group was
shorter. Nonetheless, we observed a small increase in
CSF NfL in both slow progressors (n 5 9; increase
per month 1.3% [95% CI: 0.4%, 2.1%]) and fast
progressors (n 5 7; increase per month 3.3% [95%
CI: 0.8%, 5.9%]), but no significant change in CSF
NfL levels in the Oxford intermediate group (n 5 8,
table e-3).
Baseline NfL levels in our longitudinal cohorts
were higher in the ALS-fast subgroup, in line with
findings in the cross-sectional study. The NfL blood
levels in these patients remained stable over the
15-month follow-up period. Adjustment of the
Figure 2 Summary of the longitudinal analyses of NfL levels in the London and Oxford cohorts
Observed trajectories of log NfL levels in the 15-month follow-up period for individual patients with ALS (dashed lines) and the predicted average trajectories
(solid lines) are shown for ALS-fast (red), ALS-intermediate (green), and ALS-slow (blue) patients in the London cohort (plasma, panel A) and Oxford cohort
(serum, panel B; CSF, panel C). ALS-fast: progression rate at last visit (PRL).1.0; ALS-intermediate: PRL 0.5–1.0; ALS-slow: PRL,0.5. ALS 5 amyotrophic
lateral sclerosis; NfL 5 neurofilament light chain.
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multilevel study of NfL trajectories by time from
onset of symptoms to baseline produced
only minimal changes, with no impact on the signif-
icance of the test (table e-3).
We also used cohort-specific median cutoff for
PRL to stratify patients with ALS. No change in
blood NfL levels over time were found in below-
median and above-median groups (table e-3, expo-
sure groups B), while the baseline NfL levels were
higher in the ALS above-median group in the Lon-
don/plasma (p 5 0.01) and the Oxford/serum (p 5
0.004) cohorts.
Survival analyses. Cox regression. Cox regression analysis
of survival (table 2) was examined using baseline
blood and CSF NfL levels. In the London cohort,
high levels of blood NfL, PRB, and age at symptom
onset were associated with poor survival. In the
Oxford cohort (serum), only baseline NfL levels,
but not PRB, were associated with poor survival.
When the number was increased by combining the
London and Oxford cohorts, baseline NfL levels, sex,
ALS Functional Rating Scale–Revised score at base-
line, and age at symptom onset were associated with
poor survival. Despite the much smaller case number,
CSF NfL levels were also found to be a strong, inde-
pendent prognostic biomarker for survival.
Cox regression analysis was also performed using
the time of ALS onset as the start point to evaluate
survival, while keeping the baseline (i.e., the first time
patients were sampled) as each patient’s entry time
into the study (i.e., the time from onset to baseline
was not “counted” since patients had to survive from
onset to baseline to be included in the study). Find-
ings using this approach were not dissimilar from
those in which survival was calculated from baseline
(table 2).
Kaplan–Meier. Kaplan–Meier survival curves
showed a clear separation of cumulative survivals
between subgroups of patients with ALS with differ-
ent baseline NfL levels (cohort-specific tertile cutoff
levels) in the London and in the Oxford cohorts sep-
arately and combined (figure 3, A.a–A.c).
Riluzole and blood NfL levels. Treatment with riluzole
was associated with increased risk of mortality in the
combined cohorts (hazard ratio: 1.47) (table 2). Fig-
ure 3 shows the Kaplan–Meier curves for London
(figure 3B.a) and Oxford (figure 3B.b) cohorts sepa-
rately and combined (figure 3B.c). There was no sig-
nificant difference in baseline blood NfL levels
(table 1) and clinical features (table e-2B) in patients
with ALS treated with riluzole in the London and
Oxford cohorts, separately or combined. In addition,
there was no difference in blood NfL levels in patients
with ALS stratified according to PRB between
riluzole-treated and untreated patients with ALS in
London and Oxford, separately and combined (data
not shown).
DISCUSSION Our data support blood NfL as a bio-
marker with prognostic value in ALS. In 2 indepen-
dent cohorts, there was a striking similarity in assay
sensitivity, specificity, and cutoff levels to distinguish
patients with ALS from healthy controls, while the 2
cohorts were also in agreement regarding the correla-
tion between disease progression rate and baseline
NfL levels in patients with ALS. Both cohorts showed
a steady blood NfL expression over time, and levels at
recruitment predicted survival independently from
other clinical covariates. The improved assay perfor-
mance in blood for the analysis of clinically well-
characterized cross-sectional and longitudinal
cohorts of patients with ALS supports NfL as a
reproducible, easily accessible surrogate marker of
axonal loss. In our study, NfL bioavailability in the
natural history of the disease has been truly
characterized and not predicted based on a variable
baseline measurement. NfL levels in CSF were the
best at discriminating patients with ALS from controls
and for patient stratification. This is not surprising,
considering that CSF is the natural biorepository of
products of neuroaxonal disintegration because of its
proximity to the CNS. When the total number of
ALS cases from our independent cohorts was
considered, blood NfL levels also discriminated very
well between ALS-fast, ALS-intermediate, and ALS-
slow categories. Our findings suggest that blood NfL
is now a leading candidate biomarker for improved
participant stratification in future ALS therapeutic
trials, with the additional potential for assessing
response to therapy.
Potential biases in our investigation partly reflect
the study of a rapidly disabling and life-shortening
condition. The follow-up sampling was understand-
ably more limited for the ALS-fast group, in which
it was more difficult to perform repeated measure-
ments and cohorts inevitably enriched for slower-
progressing, arguably atypical patients. By using a
multilevel model, the analysis included all individuals’
measurements under a “missing at random” assump-
tion.19 We limited the effects of the shorter follow-up
time for fast-progressing patients by restricting anal-
ysis to the first 15 months of follow-up, although
some of the cases were monitored longitudinally for
up to 3 years. Also, NfL change was jointly modeled
with the time to death within this 15-month period
to account for any informative dropout.18,20,21 Multi-
level and Cox regression analyses showed reproduc-
ible results when analyses were performed using a
variable such as disease duration from either baseline
or from symptom onset. To better characterize the
diagnostic potency of plasma NfL in ALS, future
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Table 2 Summary of Cox regression analysis for mortality in London, Oxford, and in the combined cohorts of patients with ALS
London (plasma) Oxford (serum) Combined (blood) Oxford (CSF)
No.
Cox regression analysis
No.
Cox regression analysis
No.
Cox regression analysis
No.
Cox regression analysis
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Baseline NfL levelsa
Lowest third 35 1 (ref) — 22 1 (ref) — 57 1 (ref) — 13 1 (ref) —
Middle third 34 1.91 (0.86, 4.23) 0.11 21 2.68 (0.87, 8.27) 0.09 55 2.08 (1.09, 3.97) 0.03 13 3.64 (0.77, 17.25) 0.10
Highest third 34 3.78 (1.68, 8.50) 0.001 21 6.05 (1.68, 21.87) 0.006 55 3.82 (1.98, 7.39) ,0.001 12 31.82 (3.75, 269.71) 0.002
Sex
Male 66 1 (ref) — 45 1 (ref) — 112 1 (ref) — 29 1 (ref) —
Female 37 1.41 (0.78, 2.56) 0.26 19 1.89 (0.86, 4.14) 0.11 56 1.67 (1.06, 2.63) 0.03 9 7.98 (2.07, 30.83) 0.003
Age at onset,b per year 103 1.03 (1.01, 1.06) 0.01 64 1.02 (0.98, 1.07) 0.35 167 1.03 (1.01, 1.05) 0.001 38 1.04 (0.99, 1.10) 0.11
ALSFRS-R score,b per point 103 0.96 (0.92, 1.00) 0.07 64 0.94 (0.86, 1.03) 0.18 167 0.95 (0.92, 0.99) 0.005 38 0.95 (0.85, 1.06) 0.40
Site of symptom onset
Limb 81 1 (ref) — 51 1 (ref) — 132 1 (ref) — 31 1 (ref) —
Bulbar 20 0.73 (0.37, 1.45) 0.37 13 041 (0.13, 1.34) 0.14 33 0.66 (0.38, 1.16) 0.15 7 1.13 (0.26, 4.90) 0.87
Bothc 2 1.20 (0.24, 5.86) 0.83 0 — — 2 1.11 (0.24, 5.11) 0.89 0 — —
Progression rate at baseline
Slow: <0.5 51 1 (ref) — 36 1 (ref) — 87 1 (ref) — 18 1 (ref) —
Intermediate: 0.5–1.0 30 2.44 (1.17, 5.11) 0.02 17 1.18 (0.44, 3.17) 0.74 47 1.67 (0.96, 2.90) 0.07 11 0.28 (0.05, 1.52) 0.14
Fast: >1.0 22 2.42 (1.03, 5.69) 0.04 11 0.59 (0.16, 2.14) 0.42 33 1.49 (0.77, 2.89) 0.24 9 0.10 (0.01, 0.66) 0.02
Riluzole
Without 29 1 (ref) — 34 1 (ref) — 63 1 (ref) — 19 1 (ref) —
With 74 1.54 (0.78, 3.03) 0.21 30 1.25 (0.50, 3.09) 0.63 104 1.47 (0.89, 2.41) 0.13 19 0.92 (0.23, 3.67) 0.91
Cohortd
London — — — — — — 103 1 (ref) — — — —
Oxford — — — — — — 64 0.49 (0.29, 0.81) 0.006 — — —
Abbreviations: ALS 5 amyotrophic lateral sclerosis; ALSFRS-R 5 ALS Functional Rating Scale–Revised; NfL 5 neurofilament light chain; HR 5 hazard ratio; CI 5 confidence interval; ref 5 reference.
A global test for violation of the proportional hazards assumption gave p values of 0.20, 0.21, 0.11, and 0.25 for the London (plasma), Oxford (serum), combined (blood), and Oxford (CSF) cohorts, respectively.
aCutoff values for tertiles are cohort-specific; range of NfL levels within each tertile (pg/mL): London (plasma) cohort: lowest third (n 5 35): 9.19–61.52, middle third (n 5 34): 61.74–146.36, highest third (n 5 34):
149.88–798.28; Oxford (serum) cohort: lowest third (n5 22): 11–68, middle third (n5 21): 69–129, highest third (n5 21): 130–812; Oxford (CSF) cohort: lowest third (n5 13): 1,715–4,661, middle third (n5 13):
4,673–9,483, highest third (n 5 12): 10,540–23,286.
b Tested as continuous variable in Cox regression analysis: age at onset: years; ALSFRS-R score: per point.
cOnly 2 patients were in this category.
dCohort adjustment was used in the Cox regression analysis for the combined cohort.
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studies should include other neurodegenerative disor-
ders and ALS mimics as reference, while NfL meas-
urements should be ideally undertaken closer to the
time of reported disease onset, when ALS is suspected
or at diagnosis.
NfL levels changed only minimally throughout
most of the disease course in ALS. NfL release from
affected tissues may be a prolonged downstream effect
of ALS pathology but we cannot fully comment on
earlier stages of the disease in light of the diagnostic
Figure 3 Summary of survival analyses in patients with ALS from London and Oxford cohorts separately and combined
(A) Distinct curves representing cumulative survivals in patients with ALS with different baseline plasma NfL and serum NfL levels in the London cohort (A.a),
Oxford cohort (A.b), and combined cohort (A.c). All 3 cohorts were divided by cohort-specific tertile cutoff values. (B) Kaplan–Meier curve of patients with ALS
treated with riluzole or untreated in the London cohort (B.a), Oxford cohort (B.b), and combined cohort (B.c).
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latency in our cases. It is possible that rising levels of
autoantibodies against NfL may have a clearing effect
while aggregation may reduce NfL detection, leveling
down the linear increase of NfL.22,23 Plasma levels of
axonal injury biomarkers such as total tau and S100B
were reported to be at their peak immediately after a
concussive injury and to slowly return to preinjury
levels thereafter.24 In the more prolonged process of
neurodegeneration seen in patients with ALS, the
progressive release and accumulation of Nfs may be
counterbalanced by the clearing mechanisms reported
above, resulting in a flat NfL concentration profile.
Blood NfL measurement appears to have advan-
tage over neurofilament heavy chain (NfH).8 The
“hook effect,” a potential inconsistent result due to
analyte aggregation found in measuring plasma
NfH,7,8 was not observed in the NfL assay.9 Further-
more, unlike the linear increase observed in animal
models,25 longitudinal NfH plasma expression in pa-
tients with rapidly progressing ALS showed a steady
decline as the disease advanced.8 In a clinical trial
setting, a “natural” reduction of the bioavailability
of a biomarker with the disease progression may pose
problems with the overall interpretation of treatment
response. Unlike NfH,8 blood NfL levels in ALS were
significantly higher than in controls, and maintained
distinct temporal profiles with a steady trajectory.
A change in a biomarker’s expression might be
considered as supporting evidence of disease modifi-
cation in ALS as shown in arimoclomol-treated
SOD1G93A mice of ALS,25 allowing for the reduction
of sample size and costs in clinical trials.26 The anal-
ysis of how riluzole treatment affected baseline NfL
levels in our cohorts was understandably inconclusive,
suggesting only an indication bias for the London
cohort. Nonetheless, using the same NfL assay em-
ployed in this study, we have recently shown a modest
reduction of serum NfL concentrations at different
time points following spinal cord injury in a subgroup
of patients treated with minocycline.27
Both blood and CSF NfL levels were robust inde-
pendent prognostic markers. Serial lumbar punctures
for longitudinal NfL monitoring are far less practical
than blood sampling. The observed strong correlation
between CSF and blood NfL levels suggests that blood
NfL is a surrogate marker for CSF NfL levels. The
higher blood-CSF correlation of NfL levels we
observed in patients with ALS compared with healthy
controls was puzzling. A more rapid liberation of NfL
protein from affected nervous tissue and a relatively
higher NfL concentration in CSF from patients with
ALS compared with healthy controls may determine
a more efficient redistribution of NfL protein between
CSF and blood through the blood-brain barrier. CSF
and blood matrices may act differently on NfL homeo-
stasis and clearance depending on its concentration.
Our data suggest that the measurement of blood
NfL for disease activity monitoring, in an earlier
symptomatic phase or at diagnosis, may provide fur-
ther clues on the diagnostic potency of this bio-
marker, particularly if other neurologic disorders or
ALS mimic syndromes are included as reference. In
combination with biomarkers emerging from neuro-
imaging,28 blood NfL may improve diagnostic
potency and prognostic evaluation in ALS, similar
to blood markers defining the transition between
mild cognitive impairment and Alzheimer disease29,30
used in combination with Pittsburgh compound B–
PET.31 An improved understanding of how NfL
release changes in response to pathology, in particular
presymptomatically,32 or to factors that mitigate the
disease pathology, will further strengthen the case for
NfL in the diagnostic process as well as therapeutic
trials in ALS.
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